{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:03:38Z","timestamp":1762160618401,"version":"3.32.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":6423,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["intpsychogeriatrics.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Psychogeriatrics"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1017\/s1041610207005273","type":"journal-article","created":{"date-parts":[[2007,4,16]],"date-time":"2007-04-16T09:47:34Z","timestamp":1176716854000},"page":"509-524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective"],"prefix":"10.1016","volume":"19","author":[{"given":"Karl","family":"Broich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1017\/S1041610207005273_bb0005","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1749-6632.2000.tb06412.x","article-title":"Alzheimer's disease and vascular dementia: some points of confluence","volume":"903","author":"Aguero-Torres","year":"2000","journal-title":"Annals of the New York Academy of Science"},{"key":"10.1017\/S1041610207005273_bb0010","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jalz.2006.08.004","article-title":"Commentary on \u201cChallenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials\u201d","volume":"2","author":"Aisen","year":"2006","journal-title":"Alzheimer's and Dementia"},{"year":"2000","series-title":"Diagnostic and Statistical Manual ofMental Disorders DSM-IVTR","author":"American Psychiatric Association","key":"10.1017\/S1041610207005273_bb0015"},{"key":"10.1017\/S1041610207005273_bb0020","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.clineuro.2004.10.011","article-title":"CSF biomarkers for mild cognitive impairment and early Alzheimer's disease","volume":"107","author":"Andreasen","year":"2005","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"10.1017\/S1041610207005273_bb0025","first-page":"116","article-title":"Disease modifying trials in Alzheimer disease: methodological and statistical issues","volume":"10","author":"Andrieu","year":"2006","journal-title":"Journal of Nutrition Health and Aging"},{"key":"10.1017\/S1041610207005273_bb0030","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/brain\/awl063","article-title":"CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia","volume":"129","author":"Bibl","year":"2006","journal-title":"Brain"},{"key":"10.1017\/S1041610207005273_bb0035","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimer's disease","volume":"368","author":"Blennow","year":"2006","journal-title":"Lancet"},{"key":"10.1017\/S1041610207005273_bb0040","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1177\/0269881106068299","article-title":"Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology","volume":"20","author":"Burns","year":"2006","journal-title":"Journal of Psychopharmacology"},{"key":"10.1017\/S1041610207005273_bb0045","first-page":"600","article-title":"Biomarkers in preclinical Alzheimer's disease","volume":"7","author":"Chong","year":"2006","journal-title":"Current Opinion Investigational Drugs"},{"key":"10.1017\/S1041610207005273_bb0050","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2174\/156802606776743075","article-title":"The role of MRI and PET\/SPECT in Alzheimer's disease","volume":"6","author":"Coimbra","year":"2006","journal-title":"Current Topical Medical Chemistry"},{"key":"10.1017\/S1041610207005273_bb0055","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/JAD-2005-8402","article-title":"Clinical evaluation as a biomarker for Alzheimer's disease","volume":"8","author":"Cummings","year":"2005","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1017\/S1041610207005273_bb0060","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2006.07.001","article-title":"Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials","volume":"2","author":"Cummings","year":"2006","journal-title":"Alzheimer's and Dementia"},{"key":"10.1017\/S1041610207005273_bb0065","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2796.2004.01381.x","article-title":"MRI and CSF studies in the early diagnosis of Alzheimer's disease","volume":"256","author":"de Leon","year":"2004","journal-title":"Journal of Internal Medicine"},{"key":"10.1017\/S1041610207005273_bb0070","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/089198870001300402","article-title":"Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of functional and quality of life scales","volume":"13","author":"Demers","year":"2000","journal-title":"Journal Geriatric Psychiatry and Neurology"},{"key":"10.1017\/S1041610207005273_bb0075","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1602\/neurorx.2.2.348","article-title":"Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease","volume":"2","author":"Dickerson","year":"2005","journal-title":"NeuroRx"},{"key":"10.1017\/S1041610207005273_bb0080","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1212\/WNL.48.6.1511","article-title":"The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials","volume":"48","author":"Doraiswamy","year":"1997","journal-title":"Neurology"},{"key":"10.1017\/S1041610207005273_bb0085","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/brain\/awl178","article-title":"Two-year follow-up of amyloid deposition in patients with Alzheimer's disease","volume":"129","author":"Engler","year":"2006","journal-title":"Brain"},{"key":"10.1017\/S1041610207005273_bb0090","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00002093-200104000-00008","article-title":"The disability assessment for dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease","volume":"15","author":"Feldman","year":"2001","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"Suppl. 1","key":"10.1017\/S1041610207005273_bb0095","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1017\/S1041610203009220","article-title":"General measures of cognition","volume":"15","author":"Ferris","year":"2003","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610207005273_bb0100","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1017\/S1355617705050502","article-title":"Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease","volume":"11","author":"Galasko","year":"2005","journal-title":"Journal of the International Neuropsychology Society"},{"key":"10.1017\/S1041610207005273_bb0105","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1097\/00002093-200607001-00007","article-title":"Mild cognitive impairment and the 7 uses of epidemiology","volume":"20","author":"Ganguli","year":"2006","journal-title":"Alzheimer's Disease and Associated Disorders"},{"key":"10.1017\/S1041610207005273_bb0110","series-title":"Trial Designs and Outcomes in Dementia Therapeutic Research","first-page":"113","article-title":"Functional outcomes","author":"Gauthier","year":"2006"},{"key":"10.1017\/S1041610207005273_bb0115","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.maturitas.2003.11.011","article-title":"Principles of use of surrogate markers and endpoints","volume":"47","author":"Kluft","year":"2004","journal-title":"Maturitas"},{"key":"10.1017\/S1041610207005273_bb0120","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/sim.1718","article-title":"The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint","volume":"23","author":"Mani","year":"2004","journal-title":"Statistics in Medicine"},{"key":"10.1017\/S1041610207005273_bb0125","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"key":"10.1017\/S1041610207005273_bb0130","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1017\/S1041610207005273_bb0135","doi-asserted-by":"crossref","unstructured":"Miyasaki, J. M. et al. (2006). Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 7, 996-1002.","DOI":"10.1212\/01.wnl.0000215428.46057.3d"},{"issue":"Suppl. 2","key":"10.1017\/S1041610207005273_bb0140","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","article-title":"Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope","volume":"11","author":"Mohs","year":"1997","journal-title":"The Alzheimer's Disease Cooperative Study. Alzheimer's Disease and Associated Disorders"},{"key":"10.1017\/S1041610207005273_bb0145","series-title":"Trial Designs and Outcomes in Dementia Therapeutic Research","first-page":"85","article-title":"Cognitive outcomes","author":"Nadkarni","year":"2006"},{"key":"10.1017\/S1041610207005273_bb0150","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1474-4422(04)00853-1","article-title":"PET imaging of amyloid in Alzheimer's disease","volume":"3","author":"Nordberg","year":"2004","journal-title":"Lancet Neurology"},{"key":"10.1017\/S1041610207005273_bb0155","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1034\/j.1600-0404.107.s179.8.x","article-title":"Instrumental activities of daily living: a stepping-stone towards Alzheimer's disease diagnosis in subjects with mild cognitive impairment?","volume":"179","author":"Nygard","year":"2003","journal-title":"Acta Neurologica Scandinavica Supplementum"},{"key":"10.1017\/S1041610207005273_bb0160","first-page":"137","article-title":"Measuring long-term effects and changes in the daily activities of people with dementia","volume":"10","author":"Nygard","year":"2006","journal-title":"Journal of Nutrition Health Aging"},{"key":"10.1017\/S1041610207005273_bb0165","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/089198870001300404","article-title":"Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of global scales","volume":"13","author":"Oremus","year":"2000","journal-title":"Journal ofGeriatric Psychiatry and Neurology"},{"key":"10.1017\/S1041610207005273_bb0170","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/ageing\/afj054","article-title":"Complex activities of daily living in mild cognitive impairment: conceptual and diagnostic issues","volume":"35","author":"Perneczky, R.etal.","year":"2006","journal-title":"Age and Ageing"},{"key":"10.1017\/S1041610207005273_bb0175","first-page":"394","article-title":"MCI is a clinically useful concept","volume":"18","author":"Petersen","year":"2006","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610207005273_bb0180","first-page":"59","article-title":"Toward the validation of functional neuroimaging as a potential biomarker for Alzheimer's disease: implications for drug development","volume":"7","author":"Pupi","year":"2005","journal-title":"MolecularImaging Biology"},{"key":"10.1017\/S1041610207005273_bb0185","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/S0140-6736(02)11667-9","article-title":"The dementias","volume":"360","author":"Ritchie","year":"2002","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1017\/S1041610207005273_bb0190","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1017\/S1041610203008949","article-title":"Mixed dementia: Alzheimer's and cerebrovascular disease","volume":"15","author":"Rockwood","year":"2003","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610207005273_bb0195","series-title":"Trial Designs and Outcomes in Dementia Therapeutic Research","first-page":"75","article-title":"Global Assessment Measures","author":"Rockwood","year":"2006"},{"key":"10.1017\/S1041610207005273_bb0200","series-title":"Trial Designs and Outcomes in Dementia Therapeutic Research","first-page":"131","article-title":"Quality of life outcomes","author":"Rockwood","year":"2006"},{"key":"10.1017\/S1041610207005273_bb0205","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.43.2.250","article-title":"Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop","volume":"43","author":"Romain","year":"1993","journal-title":"Neurology"},{"key":"10.1017\/S1041610207005273_bb0210","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00019442-200506000-00005","article-title":"Neuropsychiatric symptoms and quality of life in Alzheimer disease","volume":"13","author":"Shin","year":"2005","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610207005273_bb0215","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1532-5415.1996.tb01838.x","article-title":"Improved reliability of the Standardized Alzheimer's Disease Assessment Scale (SADAS) compared with the Alzheimer's Disease Assessment Scale (ADAS)","volume":"44","author":"Standish","year":"1996","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1017\/S1041610207005273_bb0220","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/089198879600900107","article-title":"Cardinal features ofcognitive dysfunction in Alzheimer's disease: a factor-analytic study ofthe Alzheimer's Disease Assessment Scale","volume":"9","author":"Talwalker","year":"1996","journal-title":"Journal ofGeriatric Psychiatry and Neurology"},{"key":"10.1017\/S1041610207005273_bb0225","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1474-4422(06)70677-9","article-title":"Disease-modifying trials in Alzheimer's disease: a European task force consensus","volume":"6","author":"Vellas","year":"2007","journal-title":"Lancet Neurology"},{"key":"10.1017\/S1041610207005273_bb0230","first-page":"402","article-title":"MCI is not a clinically useful concept","volume":"18","author":"Visser","year":"2006","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610207005273_bb0235","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00002093-200310000-00001","article-title":"Quality oflife in dementia: ten years later","volume":"17","author":"Whitehouse","year":"2003","journal-title":"AlzheimerDisease and Associated Disorders"},{"year":"2007","series-title":"The ICD-10 Classification ofMental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines","author":"World He alth Org aniz ation","key":"10.1017\/S1041610207005273_bb0240"}],"container-title":["International Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224046787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224046787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1041610207005273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:24:29Z","timestamp":1736468669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1041610224046787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S1041610224046787"],"URL":"https:\/\/doi.org\/10.1017\/s1041610207005273","relation":{},"ISSN":["1041-6102"],"issn-type":[{"type":"print","value":"1041-6102"}],"subject":[],"published":{"date-parts":[[2007,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective","name":"articletitle","label":"Article Title"},{"value":"International Psychogeriatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1017\/S1041610207005273","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 International Psychogeriatric Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}